Archive for the ‘Gene Therapy Research’ Category

[BIOS 332] Dominant and Recessive Genotypes - Jason Tresser
BIOS 332: Genetics Dominant and Recessive Genotypes October 10, 2012From:BiolaUniversityViews:2 0ratingsTime:46:16More inEducation

More:
[BIOS 332] Dominant and Recessive Genotypes - Jason Tresser - Video

[BIOS 332] Mendel #39;s Law and The Process of Meiosis - Jason Tresser
BIOS 332: Genetics Mendel #39;s Law and The Process of Meiosis September 28, 2012From:BiolaUniversityViews:4 0ratingsTime:48:58More inEducation

Continue reading here:
[BIOS 332] Mendel's Law and The Process of Meiosis - Jason Tresser - Video

[BIOS 332] Introduction to Information - Jason Tresser
BIOS 332: Genetics Introduction to Information September 24, 2012From:BiolaUniversityViews:5 0ratingsTime:16:47More inEducation

Go here to read the rest:
[BIOS 332] Introduction to Information - Jason Tresser - Video

[BIOS 332] Eukaryotic Gene Regulation - Jason Tresser
BIOS 332: Genetics Eukaryotic Gene Regulation November 28, 2012From:BiolaUniversityViews:1 0ratingsTime:47:43More inEducation

Originally posted here:
[BIOS 332] Eukaryotic Gene Regulation - Jason Tresser - Video

21 y/o Natural Bodybuilder - Polska Genetics: some posing attempts to metallica 1.90cm / 105kg
One my new favorit pull exercises. Please like subscribe and share this video with all your friends on Facebook, Twitter etc. For personal online coaching, go check out my homepage: http://www.polskagenetics.com Check out my Facebook Page for Updates and News as well. http://www.facebook.com http://www.facebook.com Intro by. http://www.youtube.comFrom:mousch66Views:599 48ratingsTime:03:26More inSports

More here:
21 y/o Natural Bodybuilder - Polska Genetics: some posing attempts to metallica 1.90cm / 105kg - Video

Washington, December 22 (ANI): In a new study, researchers have got greater insight into the safety and effectiveness of gene therapy to rebuild blood vessels in patients living with coronary artery disease.

Diagnosed with severe coronary artery disease, a group of patients too ill for or not responding to other treatment options decided to take part in a clinical trial testing angiogenic gene therapy to help rebuild their damaged blood vessels.

More than 10 years later, in a follow-up review of these patients, doctors at Baylor College of Medicine, Weill Cornell Medical College and Stony Brook University Medical Center report the outcomes are promising and open the door for larger trials to begin.

The study followed 31 Weill Cornell patients who were diagnosed with severe coronary artery disease and were given a direct injection into their heart muscle of gene therapy called adenovirus encoding angiogenic growth factor, or AdVEGF121.

Study results show the five- and 10-year survival rate of those patients were just as good and, in some cases better, than what is seen in other groups with similar heart issues treated with traditional medical therapy.

"The results of this 10-year gene therapy study are important," co-senior author Dr. Ronald G. Crystal from Weill Cornell Medical College said.

"After long-term follow-up, the patients who received angiogenic gene therapy appear to have improved outcomes. The study results give us greater insight into the safety and effectiveness of gene therapy to rebuild blood vessels in patients living with coronary artery disease," he said.

The common treatment for severe coronary artery disease is coronary artery bypass surgery, which works by redirecting blood flow around the diseased or blocked area of the heart. However, for those involved in this trial, the blood vessels that normally would be used to redirect the flow of blood were not healthy enough to do so.

In the study, patients were divided into two groups. Group A received both conventional coronary artery bypass grafting and gene therapy, while group B received only gene therapy. There was no control group.

The gene therapy helped rebuild weak and damaged blood vessels in these patients. Medical records, follow-up interviews and questionnaires were used to determine patient outcomes.

Read more here:
Gene therapy offers new ray of hope to severe coronary artery disease patients

Energy, in fact, is never lost: a fundamental law of the universe is the conservation of energy, which states that in a system isolated from all other outside factors, the total amount of energy remains the same, though transformations of energy from one form to another take place. Thermal energy is actually a form of kinetic energy generated by the movement of particles at the atomic or molecular level: the greater the movement of these particles, the greater the thermal energy. Temperature, heat, and related concepts belong to the world of physics rather than chemistry; yet it would be impossible for the chemist to work without an understanding of these properties.
When people use the word “heat” in ordinary language, what they are really referring to is “the quality of hotness”—that is, the thermal energy internal to a system. In scientific terms, however, heat is internal thermal energy that flows from one body of matter to another or, more specifically, from a system at a higher temperature to one at a lower temperature. Temperature may be defined as a measure of the average internal energy in a system. Two systems in a state of thermal equilibrium have the same temperature; on the other hand, differences in temperature determine the direction of internal energy flow between two systems where heat is being transferred.Source:
http://gundulshare.blogspot.com/2012/12/energy-heat-and-temperature.html

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/gvftjr/global) has announced the addition of the "Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) Market (2012 - 2017)" report to their offering.

Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends. Global research and development Network, Innovation and Spin offs have been discussed. The report tracks regional adoption and development trends, providing strategic recommendation to stay active and compete in the market space. An impact analysis of major drivers and restraints influencing the growth of the market is mapped for five year period.

Key Driver:

Advances in cell research and therapeutic delivery

Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market.

Key Restraint:

Home brew Reagents restricts sale of commercial kits

Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits.

Key Challenge:

Original post:
Research and Markets: Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies ...

Christmas Party 2012 - Gangnam Girls
II- Genetics Christmas Party Dec. 20, 2012 ^^ Song: Remix~ By: Remix! Dancers: April, Rox, Mai.o2, Ganda (Grace xD), Alyssa Camera: Me :DFrom:Rui Musume KageneViews:0 0ratingsTime:03:53More inEntertainment

See the original post:
Christmas Party 2012 - Gangnam Girls - Video

Plan My Baby. Baby gender predictor, Can you really choose your baby #39;s gender? Testimonial.
yupurl.com - Plan My Baby. Baby gender predictor, Can you really choose your baby #39;s gender? Testimonial. What you hear in the short video testimonial above is true story the persons who follow the this program. The owner of "Plan My Baby" program claim the method they use is 94% accurate base on some people already follow they program. Baby gender predictor is actually a controversial topic, especially in relation to genetic therapy as well as ethics of picking the sex of your respective child. While there certainly have already been advances in the field of genetics, you can get some natural and completely ethical issues that it can be done will increase the chance of deciding on a gender on your child. While no strategy is 100% accurate, for anyone who is determined to possess a boy or perhaps a girl, usually there are some issues that can be carried out to significantly grow your chances of conceiving the gender which you decide on. Remember, it is important will be to use a healthy baby, regardless of their gender. But if you need to do would like to try to decide on the gender of one #39;s child or baby gender predictor it will be easy. Some tips about what consider know. Variations in Sperm. The sperm that carry the Y chromosome are classified as the "boy" sperms, as you move the ones that carry the X chromosome are definitely the "girl" sperms. The Y sperm are faster, smaller, more agile however tend not to last as long as the "girl" sperm. The X sperm are bigger and ...From:planmybaby80Views:0 1ratingsTime:02:50More inNews Politics

Read the original post:
Plan My Baby. Baby gender predictor, Can you really choose your baby's gender? Testimonial. - Video

"Bucca" German Shepherd with strong genetics for bite work! http://www.K9-1.com
We recently were giving the opportunity to use Bucca as a stud for our most recent German Shepherd litter with our very strong and stable female Nora. This is a demo of the dog #39;s BITE and not his training. All pups will be placed with either experienced working handlers or with training and handler lessons at our facility. Dog training, personal protection dog sales, and courses for the dog training student available at our facility. Contact us at http://www.k9-1.comFrom:k91dogtrainingViews:103 4ratingsTime:02:00More inPets Animals

Originally posted here:
"Bucca" German Shepherd with strong genetics for bite work! http://www.K9-1.com - Video

Genetics in Edinburgh: the early days
A journey through the birth of genetics at Edinburgh, via our Towards Dolly projectFrom:euarchivesViews:0 0ratingsTime:02:31More inNews Politics

See more here:
Genetics in Edinburgh: the early days - Video

SEATTLE, WA--(Marketwire - Dec 20, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) today announced financial results for the third quarter of 2012, ended September 30, 2012.

"During the third quarter of 2012, we successfully completed our initial public offering of 800,000 shares at $5.00 per share, the midpoint of our price range. The proceeds from the IPO will enable us to accelerate the national roll-out of our first FDA-cleared and marketed product, the ForeCYTE Breast Health Test for breast cancer risk assessment," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO. "Our IPO was the only biotech IPO priced in the month of November and was priced in the immediate aftermath of Hurricane Sandy. I believe this is a testament to the strength of our business model and the significant revenue and earnings potential of Atossa Genetics over the next several years as we pursue the further commercialization of the ForeCYTE and ArgusCYTE tests with the 5,000-strong launch team through our marketing partner, Diagnostics Testing Group, LLC, the commercialization of two new tests in 2013, and the advancement of our intraductal therapeutics program to safely and effectively treat pre-cancerous breast lesions."

Third Quarter 2012 Results

Total revenues for the third quarter of 2012 were $105,576, comprising $104,011 in diagnostic testing services and $1,565 in product sales, versus no revenues for the third quarter of 2011. The ForeCYTE and ArgusCYTE tests were launched through a field experience trial beginning in December 2011 and are expected to be rolled out nationally starting in early 2013.

Gross margin for the third quarter was 86 percent on gross profit of $90,499.

Operating expenses are comprised of selling, general and administrative (SG&A) expenses and research and development. For the third quarter of 2012, total operating expenses were $1.23 million versus $1.27 million for the third quarter of 2011.

Net loss for the third quarter ended September 30, 2012, was $1.14 million, or ($0.10) per share, versus a net loss of $1.27 million, or ($0.11) per share, for the year-ago quarter.

As of September 30, 2012, the Company had cash and cash equivalents of $418,570 versus $1.91 million at the end of December 2011. The company completed its IPO in November 2012, raising $4.0 million in gross proceeds prior to expenses and net proceeds of approximately $3.5 million.

Corporate Highlights

About Atossa Genetics, Inc.

Read the original here:
Atossa Genetics Announces Third Quarter 2012 Financial Results

SEATTLE, WA--(Marketwire - Dec 21, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, announced today that Christopher S. Destro has joined the Company as Vice President of Sales and Marketing, reporting to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President. Mr. Destro, an industry veteran with over 16 years of successful sales and client management expertise within the clinical sector of diagnostic biotechnology, will be responsible for product marketing, distribution and sales.

"The Company is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time," said Dr. Quay. "As we accelerate the national roll-out of our ForeCYTE and ArgusCYTEBreast Health Tests in early 2013, Chris' extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives."

"Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company's products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women's lives," commented Mr. Destro. "Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa's growth as we expand the commercialization of our innovative products and services in the U.S."

Mr. Destro continued, "One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever."

From 2007 to 2011, Mr. Destro, (42), served in increasingly responsible positions including Vice President of Sales, North America, for three divisions of Magellan Biosciences, where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex and a lead care platform for Point of Care testing. In July 2011, Magellan was acquired by Thermo Fisher Scientific, where Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets.Prior to joining Magellan, Mr. Destro served as Americas Sales Director for International Bioproducts from 2000 to 2007, where he managed sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.

On December 20, 2012, and as an inducement to cause Mr. Destro to join the Company, he was awarded an option to purchase a total of 200,000 shares of common stock of the Company, par value $0.001 per share, outside the Company's 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date and vests over a four-year period from his commencement of service. This stock option was granted as an inducement material to Mr. Destro's entering into employment with the Company and is being reported in accordance with NASDAQ Listing Rule 5635(c)(4).

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

For more information about this press release, please click the following link: http://client.irwebkit.com/AtossaGenetics/media to view a video interview with Dr. Quay discussing Atossa Genetics and Christopher Destro's role with the Company. You may also sign up to receive automatic email News Alert updates.

Visit link:
Christopher S. Destro Joins Atossa Genetics as Vice President of Sales and Marketing

UMBILICAL CORD STEM CELL THERAPY
We are a Ministry of Health sanctioned group of three hospitals in South China providing adult stem cell and Cancer biotherapy treatments for patients locally and from around the world. http://www.hopestemcell.com It has been proven time and time again that adult stem cells not embryonic stem cells are safe and have remarkable results. We offer highly skilled, personalized and the most cost effective care in China which is 10 years ahead of other countries in stem cell treatment and it is delivered with the maximum regard for your safety.From:Randy RobinsonViews:0 0ratingsTime:01:54More inNews Politics

See the article here:
UMBILICAL CORD STEM CELL THERAPY - Video

Stem Cell Therapy at Integra Medical Center IMC
New Project 64From:OmarGonzalezMDViews:0 0ratingsTime:06:12More inScience Technology

View post:
Stem Cell Therapy at Integra Medical Center IMC - Video

Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012
Marie Csete, Director of Cell Therapy at AABB, spoke at the World Cord Blood Congress 2012 on the topic, #39;AABB accreditation: a global approach to collaboration, innovation and quality. #39; World Cord Blood Congress is where private and public cord blood banks, pharma and biotechs, academia and government come to debate advances in cord blood banking and therapeutics. For more information, go to http://www.terrapinn.com/cordblood. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:21:41More inScience Technology

Go here to read the rest:
Marie Csete of AABB on AABB accreditation - at World Cord Blood Congress 2012 - Video

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Dec 19, 2012) - TiGenix ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.

The interim results cover the first three months of the Phase IIa's six-month follow-up, and the data are still blinded. The primary endpoint of this study is safety, and the data collected so far support the good safety profile of all three doses of Cx611. Only two patients (4%) have suffered serious adverse events and only in one case (2%) it led to discontinuation of the treatment. All other side effects were mild and transient.

"We are delighted to report that the safety profile of Cx611 appears to be excellent," said Eduardo Bravo, CEO of TiGenix. "We have recruited patients who have failed at least two biologicals. If, in addition to this promising safety data, we can demonstrate a first indication of efficacy in this difficult to treat patient population, we will have a strong rationale to move forward with this product. We are looking forward to reporting the final results of the study at the end of April 2013."

About TiGenix

TiGenix NV ( EURONEXT BRUSSELS : TIG ) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

Forward-looking informationThis document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

See the original post here:
TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells ...

A gene network has been uncovered that could unlock the door to completely new treatments for advanced prostate cancer.

The discovery shows how genes previously not linked to the disease are activated in cancers that have become resistant to hormone treatment.

Scientists identified potential new drug targets and markers that could be used to track cancer progression.

Prostate cancer is fuelled by male hormones via a protein molecule called the androgen receptor. Standard treatment includes drugs that stop androgen hormones such as testosterone acting on prostate tumours, or cut off their supply.

But in time, the drugs stop working as the cancer overcomes its dependency on external androgens. Previous studies show how the androgen receptor attaches to and switches on specific genes to drive cancer.

The new research reveals that in tumours that are resistant to hormone therapy, the receptor activates a completely different set of genes including some associated with the production of sugar and fat.

Each year up to 41,000 men in the UK are diagnosed with prostate cancer each year and around 10,700 die from the disease. Scientists at Cambridge University made the discovery after looking at tissue samples from men with prostate cancer. The findings are published in the journal Cancer Cell.

Study leader Naomi Sharma, from the Cancer Research UK Cambridge Research Institute, said: "Our understanding so far comes from studies in cells grown in the laboratory. In this sophisticated study using samples directly from patients, we've uncovered a much more complex network of cell messages.

"These messages switch on a completely different set of genes that continue to drive the disease in men for whom standard hormone treatments have stopped working.

"These important findings provide fresh targets for the development of new drugs to treat advanced stages of prostate cancer, and new 'flags' to help doctors track the progression of the disease in patients."

Read more:
Gene find may mean new cancer drugs

NEW YORK, Dec. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p01057834/Global-Transfection-Gene-Delivery-DNA-Delivery-Protein-Delivery-SiRNA-Delivery-Technologies-Lipofection-Calcium-Phosphate-Electroporation-Nucleofection-Magnetofection-Gene-Gun-Viral-Market-2012--2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genetically_Modified_Organism,_GMO

Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends. Global research and development Network, Innovation and Spin offs have been discussed. The report tracks regional adoption and development trends, providing strategic recommendation to stay active and compete in the market space. An impact analysis of major drivers and restraints influencing the growth of the market is mapped for five year period.

Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market.

Key Restraint:

Home brewReagents restricts sale of commercial kits

Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits.

Transfection is an enabler technology which is used in many cell research activities, however only few cell lines are majorly used in these experiments restricting the scope of the study. Transfection in hard to transfect cells is the need of hour and it is a major challenge. There are few upcoming transfection technologies like nucleofection and magnetofection which are an off-shoot of electroporation, which have the potential to address these challenges but are currently cost prohibitive due to which the technologies may have a much slower uptake in the developing world.

The report also discusses new opportunities for investment in the upcoming areas like Gene therapy, Stem cell research and Electro-chemotherapy.

Different transfection technologies are analyzed through a multi-criteria based decision making process which provides competitive benchmarking. Further, the report analyses technology management strategies and technology road mapping for the forecast period. Profiles of over 20 Key companies in the area of Transfection technology sector have been provided. Key players include Life Technologies, Sigma Aldrich, Lonza, Promega, Qiagen, Bio-Rad, Roche, Polyplus Transfection, Mirius Bio, Maxcyte, etc.

Read more from the original source:
Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--

OpGen, Inc. today announced the company has entered into a scientific and technical partnership with the University of California, Davis, (UC Davis) in cooperation with the FDA supported 100K Genome Project to create high resolution microbial genetic maps.

The 100K Genome Project is a collaboration that was initiated by the U.S. Food and Drug Administration (FDA), UC Davis, and Agilent Technologies to sequence the genetic code of at least 100,000 infectious organisms and accelerate the diagnosis of foodborne illnesses. UC Davis will integrate OpGens Argus Whole Genome Mapping System into its current DNA sequencing workflow for sequence assembly and validation of the genomes.

Through the integration of OpGens Whole Genome Mapping technology, The 100K Genome Project will create a new gold standard for high-quality microbial reference genomes. These data will be used in the surveillance and management of international foodborne microbial outbreaks, and to establish a high-fidelity global reference database for microbial genomes. The 100K Genome Project will publish the genomes that are completed and validated using OpGens Whole Genome Maps to a database, providing access to the genomic maps for public health agencies throughout the world. The FDA is advocating rigorous quality control standards for this reference database whereby genomic information should be validated by two independent methods.

OpGens technology allows us to complete sequencing and provide quality control of genomes drafted by data produced using short read next-generation sequencing methods, said Bart C. Weimer, Ph.D., Professor, Department of Population and Reproduction, School of Veterinary Medicine, University of California, Davis, and Director of The 100K Pathogen Genome Project. Whole Genome Mapping provides an independent method to detect sequence variations and misassemblies, and aids us in closing the gaps. Final Whole Genome Maps will assist health agencies in outbreak management of food borne diseases which cause tremendous risk to public health.

We are pleased to be a partner in this collaboration with UC Davis and the FDA in helping to set a high-quality, validated standard for this important reference database of microbes, which pose the greatest threats to food safety and public health, said Douglas White, Chief Executive Officer of OpGen. OpGen is committed to advancing public health and providing actionable information to the healthcare community.

The Centers for Disease Control and Prevention (CDC) estimates that each year roughly one in six Americans (or 48 million people) become sick, 128,000 are hospitalized, and 3,000 die of foodborne diseases.1 There are 31 known foodborne pathogens, including Salmonella, Listeria, and E. coli, among others.1 Many of these pathogens are tracked by public health systems that track diseases and outbreaks.1 Rapid identification and detection of these pathogens can lead to more effective control and management of microbial disease outbreaks.

About ArgusWhole Genome Mapping System

OpGens Argus Whole Genome Mapping System is the only commercially available technology that can provide a high-resolution, complete visual map of a whole genome and individual chromosomes. The companys unique single molecule analysis technology provides a whole genome view that complements genome assembly and enables scientists to identify highly repetitive regions, tandem repeats and translocations that are very difficult to identify and clarify with sequencing alone. Sequencing projects can now be finished and validated with less investment in time, cost and computational effort.

About OpGen, Inc.

See more here:
OpGen Announces Partnership with University of California, Davis, to Develop High Resolution Microbial Genetic Maps in ...

NEW YORK, Dec. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0763017/United-States-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018. - 2011 company shares and distribution shares data for each of the seven market categories.- Global corporate-level profiles of key companies operating within the United States In Vitro Diagnosticsmarket. - Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the United States In Vitro Diagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 71.2 List of Figures 132 Introduction 162.1 What is This Report About? 163 In Vitro Diagnostics In United States 173.1 In Vitro Diagnostics, Market Segmentation 173.2 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 183.3 In Vitro Diagnostics Market, United States, Revenue Mix ($m), 2011 203.4 In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 213.5 In Vitro Diagnostics, United States, Company Share (2010-2011) 284 Clinical Chemistry In United States 304.1 Clinical Chemistry, Market Segmentation 304.2 Clinical Chemistry Market, United States, Revenue Mix ($m), 2011 314.3 Clinical Chemistry Market, United States, Segment Contribution (%), 2011 324.4 Clinical Chemistry Overall Revenue, (2004-2018) 334.5 Clinical Chemistry Distribution Share (2010-2011) 454.6 Clinical Chemistry, United States, Company Share (2010-2011) 465 Genetic Testing In United States 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, United States, Revenue Mix ($m), 2011 485.3 Genetic Testing Market, United States, Segment Contribution (%), 2011 495.4 Genetic Testing Overall Revenue, (2004-2018) 505.5 Genetic Testing Distribution Share (2010-2011) 545.6 Genetic Testing, United States, Company Share (2010-2011) 556 Haematology In United States 576.1 Haematology Market, Market Segmentation 576.2 Haematology Market, United States, Revenue Mix ($m), 2011 586.3 Haematology Market, United States, Segment Contribution (%), 2011 596.4 Haematology Overall Revenue, (2004-2018) 606.5 Haematology Distribution Share (2010-2011) 846.6 Haematology, United States, Company Share (2010-2011) 857 Histology And Cytology In United States 877.1 Histology and Cytology Market, Market Segmentation 877.2 Histology And Cytology Market, United States, Revenue Mix ($m), 2011 887.3 Histology And Cytology Market, United States, Segment Contribution (%), 2011 897.4 Histology And Cytology Overall Revenue, (2004-2018) 907.5 Histology And Cytology Distribution Share (2010-2011) 947.6 Histology And Cytology, United States, Company Share (2010-2011) 958 Immuno Chemistry In United States 978.1 Infectious Immunology, Market Segmentation 978.2 Immuno Chemistry Market, United States, Revenue Mix ($m), 2011 988.3 Immuno Chemistry Market, United States, Segment Contribution (%), 2011 998.4 Immuno Chemistry Overall Revenue, (2004-2018) 1008.5 Immuno Chemistry Distribution Share (2010-2011) 1288.6 Immuno Chemistry, United States, Company Share (2010-2011) 1299 Infectious Immunology In United States 1319.1 Infectious Immunology Market, United States, Revenue Mix ($m), 2011 1319.2 Infectious Immunology Market, United States, Segment Contribution (%), 2011 1329.3 Infectious Immunology Overall Revenue, (2004-2018) 1339.4 Infectious Immunology Distribution Share (2010-2011) 1419.5 Infectious Immunology, United States, Company Share (2010-2011) 14210 Microbiology Culture In United States 14410.1 Microbiology Culture, Market Segmentation 14410.2 Microbiology Culture Market, United States, Revenue Mix ($m), 2011 14510.3 Microbiology Culture Market, United States, Segment Contribution (%), 2011 14610.4 Microbiology Culture Overall Revenue, (2004-2018) 14710.5 Microbiology Culture Distribution Share (2010-2011) 15510.6 Microbiology Culture, United States, Company Share (2010-2011) 15611 Overview of Key Companies in United States In Vitro Diagnostics Market 15811.1 Siemens Healthcare 15811.2 Abbott Laboratories 15911.3 F. Hoffmann-La Roche Ltd. 16011.4 Beckman Coulter, Inc. 16111.5 Ortho-Clinical Diagnostics Inc. 16211.6 Alere Inc. 16311.7 Danaher Corporation 16411.8 bioMerieux S.A. 16411.9 Becton, Dickinson and Company 16511.10 Bio-Rad Laboratories, Inc. 16511.11 Sysmex Corporation 16611.12 Qiagen N.V. 16611.13 Gen-Probe Incorporated 16711.14 DiaSorin S.p.A 16711.15 Immucor, Inc. 16811.16 Cepheid 16811.17 Thermo Fisher Scientific Inc. 16911.18 Hologic, Inc. 16911.19 PerkinElmer, Inc. 17011.20 Grifols, S.A. 17011.21 Olympus Corporation 17111.22 Horiba, Ltd. 17111.23 Life Technologies Corporation 17211.24 Diagnostica Stago, Inc. 17211.25 ELITech Group 17311.26 OraSure Technologies, Inc. 17312 In Vitro Diagnostics Market Pipeline Products 17412.1 Clinical Chemisty Market Pipeline Products 17412.2 Immuno Chemistry Market Pipeline Products 18112.3 Haematology Market Pipeline Products 19212.4 Infectious Immunology Market Pipeline Products 19412.5 Microbiology Culture Market Pipeline Products 20112.6 Histology And Cytology Market Pipeline Products 20212.7 Genetic Testing Market Pipeline Products 20313 Financial Deals Landscape 20813.1 Acquisition 20813.2 Partnerships 23914 Recent Developments 33014.1 Strategy And Business Planning 33014.2 Research And Development 35314.3 Legal and Regulatory 35914.4 Government and Public Interest 38114.5 Product News 42815 Appendix 52515.1 Definitions of Markets Covered in the Report 52615.2 Research Methodology 53715.3 Secondary Research 53715.4 Primary Research 53815.5 Models 53815.6 Forecasts 53915.7 Expert Panels 53915.8 GlobalData Consulting 53915.9 Contact Us 54015.10 Disclaimer 540

List of Tables

Table 1: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 36Table 2: In Vitro Diagnostics Market, United States, Category Contribution (%), 2011 38Table 3: In Vitro Diagnostics Market, United States, Cross-Category Analysis, 2004-2018 40Table 4: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 42Table 5: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 44Table 6: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 46Table 7: Clinical Chemistry Market, United States, Segment Contribution (%), 2011 49Table 8: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51Table 9: Clinical Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53Table 10: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55Table 11: Clinical Chemisty Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57Table 12: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59Table 13: Urine Analysis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61Table 14: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62Table 15: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 63Table 16: Genetic Testing Market, United States, Segment Contribution (%), 2011 66Table 17: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 68Table 18: Genetic Testing, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 70Table 19: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 71Table 20: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 73Table 21: Haematology Market, United States, Segment Contribution (%), 2011 76Table 22: Haematology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 78Table 23: Haematology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 80Table 24: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82Table 25: Haematology Reagents, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84Table 26: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 86Table 27: Immunohaematology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 88Table 28: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 90Table 29: Haemostasis, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 92Table 30: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 94Table 31: Haematology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 96Table 32: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 98Table 33: Haematology Cell Counters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 100Table 34: Haematology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 101Table 35: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 103Table 36: Histology And Cytology Market, United States, Segment Contribution (%), 2011 106Table 37: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 108Table 38: Histology And Cytology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 110Table 39: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 111Table 40: Histology And Cytology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 113Table 41: Immuno Chemistry Market, United States, Segment Contribution (%), 2011 116Table 42: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 118Table 43: Immuno Chemistry, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 120Table 44: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 122Table 45: Disease Specific Immunochemistry, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 124Table 46: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 126Table 47: Drugs of Abuse / Toxicology, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 128Table 48: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 130Table 49: Endocrinology Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 132Table 50: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 134Table 51: Immunochemistry Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 136Table 52: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 138Table 53: Therapeutic Drug Monitoring, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 140Table 54: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 142Table 55: Immunochemistry Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 144Table 56: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 145Table 57: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 147Table 58: Infectious Immunology Market, United States, Segment Contribution (%), 2011 149Table 59: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 151Table 60: Infectious Immunology, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 153Table 61: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 155Table 62: Infectious Immunology Rapid Tests, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 157Table 63: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 158Table 64: Infectious Immunology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 160Table 65: Microbiology Culture Market, United States, Segment Contribution (%), 2011 163Table 66: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 165Table 67: Microbiology Culture, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 167Table 68: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 169Table 69: Microbiology Analyzers, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 171Table 70: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 172Table 71: Microbiology Culture, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 174Table 72: Clinical Chemisty Market Pipeline Products 191Table 73: Immuno Chemistry Market Pipeline Products 198Table 74: Haematology Market Pipeline Products 209Table 75: Infectious Immunology Market Pipeline Products 211Table 76: Microbiology Culture Market Pipeline Products 218Table 77: Histology And Cytology Market Pipeline Products 219Table 78: Genetic Testing Market Pipeline Products 220Table 79: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And Reagents, For $6.5 Million 225Table 80: Measurement Specialties Acquires Cambridge Technologies And Resistance Temperature Detector Company For $18.8 Million 227Table 81: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 228Table 82: AccelPath Acquires DigiPath Solutions For $2.4 Million 229Table 83: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For $324 Million 230Table 84: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services, For $17 Million 232Table 85: Leica Biosystems Completes Acquisition Of Aperio Technologies 233Table 86: Metabolon Acquires Lipomics Technologies, Diagnostics Company 235Table 87: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14 Million 237Table 88: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 238Table 89: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For $925 Million 239Table 90: Life Technologies Acquires Navigenics 241Table 91: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 243Table 92: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million 244Table 93: Systagenix Acquires O2 Insights 246Table 94: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 247Table 95: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry And Histology Services 249Table 96: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 250Table 97: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 251Table 98: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 252Table 99: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction Technologies, For $27 Million 254Table 100: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 255Table 101: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For Multiple Sclerosis 256Table 102: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 257Table 103: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 259Table 104: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 260Table 105: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 261Table 106: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 262Table 107: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System 263Table 108: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 264Table 109: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 265Table 110: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple Sclerosis Biomarkers 266Table 111: BioDot Enters Into Co-Marketing Agreement With JOT Automation 267Table 112: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 268Table 113: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And Broncus Technologies Partner To Form Broncus Medical 269Table 114: Van Andel Institute Enters Into Co-Development Agreement With Emory University 270Table 115: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 271Table 116: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing 272Table 117: Broad Institute Enters Into Distribution Agreement With Appistry For Genome Analysis Toolkit 273Table 118: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 274Table 119: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 275Table 120: Bruker Enters Into An Agreement With Nextval For High-throughput Screening Technology 276Table 121: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 277Table 122: RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 278Table 123: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory Dx For LymPro Blood Test 279Table 124: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins University School For Molecular Diagnostic Tests 280Table 125: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 281Table 126: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 282Table 127: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx 283Table 128: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 284Table 129: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 285Table 130: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For 14-3-3n Biomarker 286Table 131: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 287Table 132: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 288Table 133: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 290Table 134: Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 292Table 135: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 294Table 136: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 295Table 137: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System 296Table 138: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick Detection Platform 297Table 139: CML HealthCare Enters Into Agreement With MaRS Innovation 298Table 140: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 299Table 141: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery 300Table 142: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics 301Table 143: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 302Table 144: Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 303Table 145: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 304Table 146: ImaginAb Enters Into Co-Development Agreement With MacroGenics 305Table 147: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 306Table 148: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 307Table 149: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 308Table 150: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 309Table 151: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 310Table 152: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 311Table 153: University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 312Table 154: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 313Table 155: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 314Table 156: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 315Table 157: Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 316Table 158: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 317Table 159: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 318Table 160: Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 319Table 161: Molecular Targeting Technologies Enters Into Licensing Agreement With Medical College of Wisconsin For 99mTc-HYNIC-Duramycin 320Table 162: Rosetta Genomics Enters Into Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 321Table 163: Bio-Rad Labs Enters Into Distribution Agreement With Myriad RBM For Multiplex Biomarker Kits 322Table 164: Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 323Table 165: OriGene Technologies Enters Into Co-Development Agreement With Centre of Excellence for Prevention of Organ Failure 324Table 166: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 325Table 167: IRIS International Enters Into Distribution Agreement With Alifax 326Table 168: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 327Table 169: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 328Table 170: Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 329Table 171: RS Medical Enters Into Distribution Agreement With Harvest Technologies 330Table 172: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 331Table 173: Sandia National Labs Plans To Enter Into Licensing Agreement For SpinDx, Medical Diagnostic Tool 332Table 174: HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 333Table 175: Genisphere Enters Into Co-Development Agreement With Lankenau Institute for Medical Research 334Table 176: WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies 335Table 177: BioView Enters Into Co-Development Agreement With ScreenCell For Circulating Tumor Cell Analysis Technology 336Table 178: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 337Table 179: Fluxion Biosciences Enters Into Co-Development Agreement With Stanford University School of Medicine 338Table 180: Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 339Table 181: Phenomenome Discoveries Enters Into Licensing Agreement With Polymedco For Cancer Diagnostic Test 340Table 182: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 341Table 183: PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 342Table 184: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays 343Table 185: Stratos Enters Into Co- Development Agreement With nanoMR 344Table 186: Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 345Table 187: Berg Pharma Enters Into Co-Development Agreement With Parkinson's Institute 346

Read the original here:
United States In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology ...

genetics @ tonic room 12/16/12
From:lizeduslapedusViews:1 0ratingsTime:07:07More inMusic

See more here:
genetics @ tonic room 12/16/12 - Video

genetics @ tonic room III 12/16/12
From:lizeduslapedusViews:0 0ratingsTime:08:45More inMusic

Link:
genetics @ tonic room III 12/16/12 - Video

genetics @ tonic room II 12/16/12
From:lizeduslapedusViews:0 0ratingsTime:05:40More inMusic

Read the original:
genetics @ tonic room II 12/16/12 - Video